
IDEXX Laboratories, Inc. – NASDAQ:IDXX
IDEXX Laboratories stock price today
IDEXX Laboratories stock price monthly change
IDEXX Laboratories stock price quarterly change
IDEXX Laboratories stock price yearly change
IDEXX Laboratories key metrics
Market Cap | 33.61B |
Enterprise value | 40.74B |
P/E | 60.22 |
EV/Sales | 12.09 |
EV/EBITDA | 40.26 |
Price/Sales | 11.87 |
Price/Book | 65.68 |
PEG ratio | -8.48 |
EPS | 10.43 |
Revenue | 3.72B |
EBITDA | 1.15B |
Income | 866.56M |
Revenue Q/Q | 7.09% |
Revenue Y/Y | 8.56% |
Profit margin | 20.17% |
Oper. margin | 26.69% |
Gross margin | 59.52% |
EBIT margin | 26.69% |
EBITDA margin | 30.87% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeIDEXX Laboratories stock price history
IDEXX Laboratories stock forecast
IDEXX Laboratories financial statements
Jun 2023 | 943.63M | 224.23M | 23.76% |
---|---|---|---|
Sep 2023 | 915.52M | 212.23M | 23.18% |
Dec 2023 | 901.60M | 194.52M | 21.58% |
Mar 2024 | 964.09M | 235.57M | 24.44% |
Sep 2025 | 1.10B | 269.04M | 24.4% |
---|---|---|---|
Oct 2025 | 1.08B | 266.78M | 24.6% |
Dec 2025 | 1.06B | 250.82M | 23.51% |
Mar 2026 | 1.17B | 302.15M | 25.7% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 2870806000 | 1.77B | 61.9% |
---|---|---|---|
Sep 2023 | 3086404000 | 1.78B | 57.96% |
Dec 2023 | 3259925000 | 1.77B | 54.46% |
Mar 2024 | 3353515000 | 1.78B | 53.22% |
Jun 2023 | 200.31M | -27.47M | -151.03M |
---|---|---|---|
Sep 2023 | 272.43M | -27.83M | -43.03M |
Dec 2023 | 249.85M | -30.43M | -101.84M |
Mar 2024 | 198.58M | -106.94M | -144.07M |
IDEXX Laboratories alternative data
IDEXX
12 Feb 2023 | 81 |
---|---|
19 Feb 2023 | 85 |
26 Feb 2023 | 84 |
5 Mar 2023 | 78 |
12 Mar 2023 | 78 |
19 Mar 2023 | 79 |
26 Mar 2023 | 87 |
2 Apr 2023 | 85 |
9 Apr 2023 | 83 |
16 Apr 2023 | 82 |
23 Apr 2023 | 79 |
30 Apr 2023 | 74 |
7 May 2023 | 71 |
14 May 2023 | 89 |
21 May 2023 | 87 |
28 May 2023 | 72 |
4 Jun 2023 | 79 |
11 Jun 2023 | 77 |
18 Jun 2023 | 74 |
25 Jun 2023 | 52 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
Sep 2023 | 208 |
---|---|
Oct 2023 | 184 |
Nov 2023 | 195 |
Dec 2023 | 198 |
Jan 2024 | 186 |
Feb 2024 | 178 |
Apr 2024 | 240 |
May 2024 | 262 |
Jun 2024 | 202 |
Jul 2024 | 215 |
Sep 2023 | 11,000 |
---|---|
Oct 2023 | 11,000 |
Nov 2023 | 11,000 |
Dec 2023 | 11,000 |
Jan 2024 | 11,000 |
Feb 2024 | 11,000 |
Mar 2024 | 11,000 |
Apr 2024 | 11,000 |
May 2024 | 11,000 |
Jun 2024 | 11,000 |
Jul 2024 | 11,000 |
IDEXX Laboratories other data
Period | Buy | Sel |
---|---|---|
Dec 2023 | 0 | 18764 |
Feb 2024 | 0 | 43524 |
Mar 2024 | 0 | 9508 |
May 2024 | 0 | 200 |
Sep 2024 | 0 | 500 |
Nov 2024 | 0 | 344 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | VANDEBROEK SOPHIE V. director | Common Stock | 344 | $420.44 | $144,630 | ||
Sale | SZOSTAK M ANNE director | Common Stock | 500 | $469.37 | $234,686 | ||
Option | SCHRECK MICHAEL officer: Executive Vice President | Common Stock | 164 | N/A | N/A | ||
Option | SCHRECK MICHAEL officer: Executive Vice President | Restricted Stock Unit | 164 | N/A | N/A | ||
Option | SMITH MARTIN ALEXANDER officer: Executive Vice President | Common Stock | 18 | N/A | N/A | ||
Option | SMITH MARTIN ALEXANDER officer: Executive Vice President | Restricted Stock Unit | 18 | N/A | N/A | ||
Option | MCKEON BRIAN P officer: EVP, CFO.. | Common Stock | 192 | N/A | N/A | ||
Option | MCKEON BRIAN P officer: EVP, CFO.. | Restricted Stock Unit | 192 | N/A | N/A | ||
Option | MAZELSKY JONATHAN JAY director, officer.. | Common Stock | 384 | N/A | N/A | ||
Option | MAZELSKY JONATHAN JAY director, officer.. | Restricted Stock Unit | 384 | N/A | N/A |
Patent |
---|
Application Filling date: 28 Feb 2022 Issue date: 8 Sep 2022 |
Grant Utility: Markers for renal disease Filling date: 16 Sep 2019 Issue date: 6 Sep 2022 |
Application Filling date: 17 Feb 2022 Issue date: 1 Sep 2022 |
Grant Filling date: 19 Oct 2018 Issue date: 23 Aug 2022 |
Application Filling date: 28 Mar 2022 Issue date: 14 Jul 2022 |
Application Filling date: 17 Dec 2021 Issue date: 23 Jun 2022 |
Grant Filling date: 8 Apr 2019 Issue date: 14 Jun 2022 |
Application Filling date: 10 Feb 2022 Issue date: 2 Jun 2022 |
Application Filling date: 9 Jun 2021 Issue date: 5 May 2022 |
Application Filling date: 30 Sep 2021 Issue date: 31 Mar 2022 |
Quarter | Transcript |
---|---|
Q1 2024 1 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 5 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 1 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 1 Aug 2023 | Q2 2023 Earnings Call Transcript |
Zoetis: Poised For Growth Yet Priced For Decline (Rating Upgrade To Strong Buy)
IDEXX Laboratories: A Business With Strong Fundamentals
IDEXX Laboratories: Growth Remains Despite Weak Clinical Visits
Looking For Fast Growth In Healthcare? IDEXX Has You Covered
Illumina: The Divestiture Of Grail Could Unlock Significant Shareholder Value
IDEXX: A Realistic Path To 12-14% Annual Returns
IDEXX Laboratories: Long-Term Growth Remains Attractive
IDEXX: One Of The Best Compounders On The Market
IDEXX Laboratories: Excellent Business But Extremely Overpriced
-
What's the price of IDEXX Laboratories stock today?
One share of IDEXX Laboratories stock can currently be purchased for approximately $636.75.
-
When is IDEXX Laboratories's next earnings date?
Unfortunately, IDEXX Laboratories's (IDXX) next earnings date is currently unknown.
-
Does IDEXX Laboratories pay dividends?
No, IDEXX Laboratories does not pay dividends.
-
How much money does IDEXX Laboratories make?
IDEXX Laboratories has a market capitalization of 33.61B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 8.72% to 3.66B US dollars.
-
What is IDEXX Laboratories's stock symbol?
IDEXX Laboratories, Inc. is traded on the NASDAQ under the ticker symbol "IDXX".
-
What is IDEXX Laboratories's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of IDEXX Laboratories?
Shares of IDEXX Laboratories can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are IDEXX Laboratories's key executives?
IDEXX Laboratories's management team includes the following people:
- Mr. Jonathan J. Mazelsky Pres, Chief Executive Officer & Director(age: 64, pay: $2,540,000)
- Mr. Brian P. McKeon Chief Financial Officer, Executive Vice President & Treasurer(age: 63, pay: $1,350,000)
- Mr. James F. Polewaczyk Executive Vice President & Chief Commercial Officer(age: 61, pay: $1,110,000)
- Mr. Michael J. Lane Executive Vice President and GM of Reference Laboratories & Information Technology(age: 57, pay: $1,110,000)
- Ms. Sharon E. Underberg Senior Vice President, Gen. Counsel & Corporation Sec.(age: 64, pay: $881,050)
- Mr. Jonathan W. Ayers Senior Advisor & Director(age: 69, pay: $169,870)
-
How many employees does IDEXX Laboratories have?
As Jul 2024, IDEXX Laboratories employs 11,000 workers.
-
When IDEXX Laboratories went public?
IDEXX Laboratories, Inc. is publicly traded company for more then 34 years since IPO on 21 Jun 1991.
-
What is IDEXX Laboratories's official website?
The official website for IDEXX Laboratories is idexx.com.
-
Where are IDEXX Laboratories's headquarters?
IDEXX Laboratories is headquartered at One IDEXX Drive, Westbrook, ME.
-
How can i contact IDEXX Laboratories?
IDEXX Laboratories's mailing address is One IDEXX Drive, Westbrook, ME and company can be reached via phone at +20 75560300.
IDEXX Laboratories company profile:

IDEXX Laboratories, Inc.
idexx.comNASDAQ
11,000
Medical - Diagnostics & Research
Healthcare
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Westbrook, ME 04092
CIK: 0000874716
ISIN: US45168D1046
CUSIP: 45168D104